Hypercholesterolemia and microvascular dysfunction: interventional strategies

What Do My Cholesterol Levels Mean?. American Heart Association. 2007, 6-22-2009 Lloyd-Jones D, Adams R, Carnethon M, De SG, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K: Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009, 119: e21-181. 10.1161/CIRCULATIONAHA.108.191261. Segrest JP: The role of non-LDL:non-HDL particles in atherosclerosis. Curr Diab Rep. 2002, 2: 282-288. 10.1007/s11892-002-0096-0. Selvin E, Erlinger TP: Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004, 110: 738-743. 10.1161/01.CIR.0000137913.26087.F0. Hayakawa H, Raij L: Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. J Hypertens. 1999, 17: 611-619. 10.1097/00004872-199917050-00004. Choudhury RP, Fuster V, Fayad ZA: Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov. 2004, 3: 913-925. 10.1038/nrd1548. Kang J, Albadawi H, Patel VI, Abbruzzese TA, Yoo JH, Austen WG, Watkins MT: Apolipoprotein E-/- mice have delayed skeletal muscle healing after hind limb ischemia-reperfusion. J Vasc Surg. 2008, 48: 701-708. 10.1016/j.jvs.2008.04.006. Stapleton PA, Goodwill AG, James ME, D'Audiffret AC, Frisbee JC: Differential impact of familial hypercholesterolemia and combined hyperlipidemia on vascular wall and network remodeling in mice. Microcirculation. 2010, 17: 47-58. 10.1111/j.1549-8719.2009.00003.x. Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA: Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther. 2008, 6: 567-581. 10.1586/14779072.6.4.567. Boodhwani M, Nakai Y, Mieno S, Voisine P, Bianchi C, Araujo EG, Feng J, Michael K, Li J, Sellke FW: Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann Thorac Surg. 2006, 81: 634-641. 10.1016/j.athoracsur.2005.07.090. Drolet MC, Plante E, Battistini B, Couet J, Arsenault M: Early endothelial dysfunction in cholesterol-fed rabbits: a non-invasive in vivo ultrasound study. Cardiovasc Ultrasound. 2004, 2: 10-10.1186/1476-7120-2-10. Stapleton PA, Goodwill AG, James ME, Frisbee JC: Altered mechanisms of endothelium-dependent dilation in skeletal muscle arterioles with genetic hypercholesterolemia. Am J Physiol Regul Integr Comp Physiol. 2007, 293: R1110-R1119. Wolfle SE, de Wit C: Intact endothelium-dependent dilation and conducted responses in resistance vessels of hypercholesterolemic mice in vivo. J Vasc Res. 2005, 42: 475-482. 10.1159/000088101. Jiang F, Gibson AP, Dusting GJ: Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice. Eur J Pharmacol. 2001, 424: 141-149. 10.1016/S0014-2999(01)01140-2. Goodwill AG, Stapleton PA, James ME, D'Audiffret AC, Frisbee JC: Increased arachidonic acid-induced thromboxane generation impairs skeletal muscle arteriolar dilation with genetic dyslipidemia. Microcirculation. 2008, 15: 621-631. 10.1080/10739680802308334. Kauser K, da C, Fitch R, Mallari C, Rubanyi GM: Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol. 2000, 278: H1679-H1685. Pfister SL, Falck JR, Campbell WB: Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am J Physiol. 1991, 261: H843-H852. Stokes KY, Calahan L, Russell JM, Gurwara S, Granger DN: Role of platelets in hypercholesterolemia-induced leukocyte recruitment and arteriolar dysfunction. Microcirculation. 2006, 13: 377-388. 10.1080/10739680600745877. Stokes KY, Cooper D, Tailor A, Granger DN: Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med. 2002, 33: 1026-1036. 10.1016/S0891-5849(02)01015-8. Vladimirova-Kitova L, Deneva T, Angelova E, Nikolov F, Marinov B, Mateva N: Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging. 2008, 28: 417-425. 10.1111/j.1475-097X.2008.00825.x. White CR, Parks DA, Patel RP, Shelton J, Tarpey MM, Freeman BA, rley-Usmar VM: L-Arginine inhibits xanthine oxidase-dependent endothelial dysfunction in hypercholesterolemia. FEBS Lett. 2004, 561: 94-98. 10.1016/S0014-5793(04)00137-1. Cannon RO: Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998, 44: 1809-1819. Aggarwal NT, Pfister SL, Campbell WB: Hypercholesterolemia enhances 15-lipoxygenase-mediated vasorelaxation and acetylcholine-induced hypotension. Arterioscler Thromb Vasc Biol. 2008, 28: 2209-2215. 10.1161/ATVBAHA.108.177113. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA: A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007, 27: 1803-1810. 10.1161/ATVBAHA.107.145151. Stancu C, Sima A: Statins: mechanism of action and effects. J Cell Mol Med. 2001, 5: 378-387. 10.1111/j.1582-4934.2001.tb00172.x. Dilaveris P, Giannopoulos G, Riga M, Synetos A, Stefanadis C: Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol. 2007, 5: 227-237. 10.2174/157016107781024091. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005, 366: 1267-1278. 10.1016/S0140-6736(05)67394-1. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE: Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet. 2008, 72: 485-498. 10.1111/j.1469-1809.2008.00436.x. Goldstein JL, Hobbs HH, Brown MS: Familial hypercholesterolemia. The metabolic and molecular bases of inherited diseases. Edited by: Scriver CR, Beaudet AL, Sly WS. 2001, New York: McGraw-Hill Book Co, 2863-2913. McNeely MJ, Edwards KL, Marcovina SM, Brunzell JD, Motulsky AG, Austin MA: Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis. 2001, 159: 471-481. 10.1016/S0021-9150(01)00528-7. Goligorsky MS: Endothelial cell dysfunction: can't live with it, how to live without it. Am J Physiol Renal Physiol. 2005, 288: F871-F880. 10.1152/ajprenal.00333.2004. Ogita H, Liao J: Endothelial function and oxidative stress. Endothelium. 2004, 11: 123-132. 10.1080/10623320490482664. Woodman CR, Ingram D, Bonagura J, Laughlin MH: Exercise training improves femoral artery blood flow responses to endothelium-dependent dilators in hypercholesterolemic pigs. Am J Physiol Heart Circ Physiol. 2006, 290: H2362-H2368. 10.1152/ajpheart.01026.2005. Stokes KY, Russell JM, Jennings MH, Alexander JS, Granger DN: Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. Free Radic Biol Med. 2007, 43: 22-30. 10.1016/j.freeradbiomed.2007.02.027. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 1994, 93: 50-55. 10.1172/JCI116983. Mietus-Snyder M, Malloy MJ: Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy. J Pediatr. 1998, 133: 35-40. 10.1016/S0022-3476(98)70174-X. Henderson KK, Turk JR, Rush JW, Laughlin MH: Endothelial function in coronary arterioles from pigs with early-stage coronary disease induced by high-fat, high-cholesterol diet: effect of exercise. J Appl Physiol. 2004, 97: 1159-1168. 10.1152/japplphysiol.00261.2004. Ingram DG, Newcomer SC, Price EM, Eklund KE, McAllister RM, Laughlin MH: Chronic nitric oxide synthase inhibition blunts endothelium-dependent function of conduit coronary arteries, not arterioles. Am J Physiol Heart Circ Physiol. 2007, 292: H2798-H2808. 10.1152/ajpheart.00899.2006. Green DJ, Walsh JH, Maiorana A, Burke V, Taylor RR, O'Driscoll JG: Comparison of resistance and conduit vessel nitric oxide-mediated vascular function in vivo: effects of exercise training. J Appl Physiol. 2004, 97: 749-755. 10.1152/japplphysiol.00109.2004. Walsh JH, Yong G, Cheetham C, Watts GF, O'Driscoll GJ, Taylor RR, Green DJ: Effects of exercise training on conduit and resistance vessel function in treated and untreated hypercholesterolaemic subjects. Eur Heart J. 2003, 24: 1681-1689. 10.1016/S0195-668X(03)00384-1. Aggarwal NT, Pfister SL, Gauthier KM, Chawengsub Y, Baker JE, Campbell WB: Chronic hypoxia enhances 15-lipoxygenase-mediated vasorelaxation in rabbit arteries. Am J Physiol Heart Circ Physiol. 2009, 296: H678-H688. 10.1152/ajpheart.00777.2008. Wassmann S, Nickenig G: Interrelationship of free oxygen radicals and endothelial dysfunction--modulation by statins. Endothelium. 2003, 10: 23-33. 10.1080/10623320303357. Pfister SL, Spitzbarth N, Edgemond W, Campbell WB: Vasorelaxation by an endothelium-derived metabolite of arachidonic acid. Am J Physiol. 1996, 270: H1021-H1030. Pfister SL: Characterization of endothelial thromboxane receptors in rabbit aorta. Prostaglandins Other Lipid Mediat. 2008, 87: 54-61. 10.1016/j.prostaglandins.2008.08.002. Pfister SL: Aortic thromboxane receptor deficiency alters vascular reactivity in cholesterol-fed rabbits. Atherosclerosis. 2006, 189: 358-363. 10.1016/j.atherosclerosis.2006.02.004. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK: Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004, 114: 784-794. Keulen ET, Schaper NC, Houben AJ, van Lin JM, Lutgens I, Rijkers K, linga-Thie GM, de Bruin TW: Reduced structural and functional skin capillaries in familial combined hyperlipidemia affected men, associated with increased remnant-like lipoprotein cholesterol levels. Atherosclerosis. 2002, 163: 355-362. 10.1016/S0021-9150(02)00021-7. Pitkanen OP, Raitakari OT, Niinikoski H, Nuutila P, Iida H, Voipio-Pulkki LM, Harkonen R, Wegelius U, Ronnemaa T, Viikari J: Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol. 1996, 28: 1705-1711. 10.1016/S0735-1097(96)00376-2. Kaufmann PA, Gnecchi-Ruscone T, Schafers KP, Luscher TF, Camici PG: Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol. 2000, 36: 103-109. 10.1016/S0735-1097(00)00697-5. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988, 33: 667-672. 10.1038/ki.1988.51. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005, 42: 473-480. 10.1002/hep.20781. Scalia R, Appel JZ, Lefer AM: Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit: role of P-selectin, ICAM-1, and VCAM-1. Arterioscler Thromb Vasc Biol. 1998, 18: 1093-1100. Stokes KY, Calahan L, Hamric CM, Russell JM, Granger DN: CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol. 2009, 296: H689-H697. 10.1152/ajpheart.00962.2008. Pasceri V, Cheng JS, Willerson JT, Yeh ET: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001, 103: 2531-2534. Nelken NA, Coughlin SR, Gordon D, Wilcox JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991, 88: 1121-1127. 10.1172/JCI115411. Stapleton PA, Goodwill AG, James ME, D'Audiffret AC, Frisbee JC: Differential Impact of Familial Hypercholesterolemia and Combined Hyperlipidemia on Vascular Wall and Network Remodeling in Mice. Microcirculation. 2010, 17: 47-58. 10.1111/j.1549-8719.2009.00003.x. Simionescu M: Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol. 2007, 27: 266-274. 10.1161/01.ATV.0000253884.13901.e4. Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G, Luscher TF: Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol. 2006, 47 (Suppl 2): S136-S150. 10.1097/00005344-200606001-00008. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama S, Yamanishi H, Matsumoto M, Hori M: C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001, 104: 63-67. 10.1161/hc2601.091705. Calabro P, Yeh ET: The pleiotropic effects of statins. Curr Opin Cardiol. 2005, 20: 541-546. 10.1097/01.hco.0000181482.99067.bf. Harrison DG: Endothelial function and oxidant stress. Clin Cardiol. 1997, 20: II-7. Cave A: Selective targeting of NADPH oxidase for cardiovascular protection. Curr Opin Pharmacol. 2009, 9: 208-213. 10.1016/j.coph.2008.10.001. Schulz E, Munzel T: NOX5, a new "radical" player in human atherosclerosis?. J Am Coll Cardiol. 2008, 52: 1810-1812. 10.1016/j.jacc.2008.08.040. Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006, 113: 1708-1714. 10.1161/CIRCULATIONAHA.105.602532. Faraci FM, Didion SP: Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol. 2004, 24: 1367-1373. 10.1161/01.ATV.0000133604.20182.cf. Guo Z, Ran Q, Roberts LJ, Zhou L, Richardson A, Sharan C, Wu D, Yang H: Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic Biol Med. 2008, 44: 343-352. 10.1016/j.freeradbiomed.2007.09.009. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000, 87: 840-844. Berliner JA, Watson AD: A role for oxidized phospholipids in atherosclerosis. N Engl J Med. 2005, 353: 9-11. 10.1056/NEJMp058118. Mugge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res. 1991, 69: 1293-1300. Sakurai K, Sawamura T: Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci. 2003, 91: 182-186. 10.1254/jphs.91.182. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005, 353: 46-57. 10.1056/NEJMoa043175. Kinlay S: Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007, 49: 2003-2009. 10.1016/j.jacc.2007.01.083. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK: Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009, 119: 131-138. 10.1161/CIRCULATIONAHA.108.813311. Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, Wilkinson IB: Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol. 2007, 50: 852-858. 10.1016/j.jacc.2007.04.076. Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM: Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009, 103: 369-374. 10.1016/j.amjcard.2008.09.090. Jasinska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep. 2007, 59: 483-499. Vlachopoulos C, Aznaouridis K, Dagre A, Vasiliadou C, Masoura C, Stefanadi E, Skoumas J, Pitsavos C, Stefanadis C: Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. Eur Heart J. 2007, 28: 2102-2109. 10.1093/eurheartj/ehm247. Grodzinska L, Starzyk D, Bieron K, Goszcz A, Korbut R: Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study. Basic Clin Pharmacol Toxicol. 2005, 96: 413-419. 10.1111/j.1742-7843.2005.pto_96603.x. Laufs U: Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003, 58: 719-731. Miura S, Saku K: Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med. 2008, 47: 1165-1170. 10.2169/internalmedicine.47.1099. Robinson JG, Davidson MH: Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006, 4: 461-476. 10.1586/14779072.4.4.461. Cole P, Rabasseda X: Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet. Drugs Today (Barc). 2005, 41: 317-327. 10.1358/dot.2005.41.5.893614. Sirvent P, Mercier J, Lacampagne A: New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008, 8: 333-338. 10.1016/j.coph.2007.12.010. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001, 21: 1712-1719. 10.1161/hq1101.098486. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T: Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation. 2002, 105: 933-938. 10.1161/hc0802.104283. Hoffman R, Brook GJ, Aviram M: Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis. 1992, 93: 105-113. 10.1016/0021-9150(92)90204-T. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000, 20: 61-69. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J: Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol. 2008, 65: 637-645. 10.1111/j.1365-2125.2007.03080.x. Tuzcu EM, Nicholls SJ: Statins targeting inflammation by lowering low-density lipoprotein?. J Am Coll Cardiol. 2007, 49: 2010-2012. 10.1016/j.jacc.2007.03.011. Yusuf S, Lonn E, Bosch J: Lipid lowering for primary prevention. Lancet. 2009, 373: 1152-1155. 10.1016/S0140-6736(09)60357-3. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999, 100: 230-235. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las HN, Cachofeiro V, Luno J: Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem. 2007, 14: 243-248. 10.2174/092986707779313381. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, Diaz C, Hernandez G, Egido J: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998, 32: 2057-2064. 10.1016/S0735-1097(98)00487-2. Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, Kim DW, Kim YK, Ro HK, Shong M: Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med. 2002, 34: 451-461. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD: Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998, 339: 12-20. 10.1056/NEJM199807023390103. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A: Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007, 39: 1423-1434. 10.1249/mss.0b013e3180616b27. Kingwell BA: Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB J. 2000, 14: 1685-1696. 10.1096/fj.99-0896rev. Maxwell AJ, Schauble E, Bernstein D, Cooke JP: Limb blood flow during exercise is dependent on nitric oxide. Circulation. 1998, 98: 369-374. Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL, DuBose KD: Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports Med. 2001, 31: 1033-1062. 10.2165/00007256-200131150-00002. Goto C, Nishioka K, Umemura T, Jitsuiki D, Sakagutchi A, Kawamura M, Chayama K, Yoshizumi M, Higashi Y: Acute moderate-intensity exercise induces vasodilation through an increase in nitric oxide bioavailiability in humans. Am J Hypertens. 2007, 20: 825-830. 10.1016/j.amjhyper.2007.02.014. de Moraes C, Davel AP, Rossoni LV, Antunes E, Zanesco A: Exercise training improves relaxation response and SOD-1 expression in aortic and mesenteric rings from high caloric diet-fed rats. BMC Physiol. 2008, 8: 12-10.1186/1472-6793-8-12. Bai Y, Sigala W, Adams GR, Vaziri ND: Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol. 2009, 29: 213-221. 10.1159/000156715. Peake J, Nosaka K, Suzuki K: Characterization of inflammatory responses to eccentric exercise in humans. Exerc Immunol Rev. 2005, 11: 64-85. Pedersen BK, Febbraio MA: Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008, 88: 1379-1406. 10.1152/physrev.90100.2007. Pedersen BK: The diseasome of physical inactivity--and the role of myokines in muscle--fat cross talk. J Physiol. 2009, 587: 5559-5568. 10.1113/jphysiol.2009.179515. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP: Role of myokines in exercise and metabolism. J Appl Physiol. 2007, 103: 1093-1098. 10.1152/japplphysiol.00080.2007. Pedersen BK, Fischer CP: Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care. 2007, 10: 265-271. 10.1097/MCO.0b013e3280ebb5b3. Pedersen BK, Hoffman-Goetz L: Exercise and the immune system: regulation, integration, and adaptation. Physiol Rev. 2000, 80: 1055-1081. Reese EP: Arthritis; the use of physical therapy as an aspect of management. Calif Med. 1958, 89: 204-209. Oberbach A, Lehmann S, Kirsch K, Krist J, Sonnabend M, Linke A, Tonjes A, Stumvoll M, Bluher M, Kovacs P: Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene. Eur J Endocrinol. 2008, 159: 129-136. 10.1530/EJE-08-0220. Lemos ET, Reis F, Baptista S, Pinto R, Sepodes B, Vala H, Rocha-Pereira P, Silva GC, Teixeira N, Silva AS: Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition. 2008, 25: 330-9. 10.1016/j.nut.2008.08.014. Wilund KR: Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?. Clin Sci (Lond). 2007, 112: 543-555. 10.1042/CS20060368. Rich PR: The molecular machinery of Keilin's respiratory chain. Biochem Soc Trans. 2003, 31: 1095-1105. 10.1042/BST0311095. Bloomer RJ: Effect of exercise on oxidative stress biomarkers. Adv Clin Chem. 2008, 46: 1-50. full_text. Ji LL: Antioxidants and oxidative stress in exercise. Proc Soc Exp Biol Med. 1999, 222: 283-292. 10.1046/j.1525-1373.1999.d01-145.x. Brennan ML, Penn MS, Van LF, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003, 349: 1595-1604. 10.1056/NEJMoa035003. Meilhac O, Ramachandran S, Chiang K, Santanam N, Parthasarathy S: Role of arterial wall antioxidant defense in beneficial effects of exercise on atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2001, 21: 1681-1688. 10.1161/hq1001.097106. Mignini F, Tomassoni D, Traini E, Streccioni V: Antioxidant endogenous defense in a human model of physical stress. Clin Exp Hypertens. 2008, 30: 776-784. 10.1080/07420520802572341. Seals DR, Desouza CA, Donato AJ, Tanaka H: Habitual exercise and arterial aging. J Appl Physiol. 2008, 105: 1323-1332. 10.1152/japplphysiol.90553.2008. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG: Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest. 2000, 105: 1631-1639. 10.1172/JCI9551. Sun MW, Zhong MF, Gu J, Qian FL, Gu JZ, Chen H: Effects of different levels of exercise volume on endothelium-dependent vasodilation: roles of nitric oxide synthase and heme oxygenase. Hypertens Res. 2008, 31: 805-816. 10.1291/hypres.31.805. de Winther MP, Kanters E, Kraal G, Hofker MH: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005, 25: 904-914. 10.1161/01.ATV.0000160340.72641.87.